London, 28 April 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have supported COMPASS Pathways, a mental health care company, on the international communication of its $80 million Series B fundraise.
The funding will enable COMPASS to expand beyond its lead programme investigating psilocybin therapy for treatment-resistant depression, supporting research into additional indications, advancing the company’s preclinical pipeline, developing digital technologies, and establishing new academic and clinical research partnerships. COMPASS is conducting the world’s first large-scale psilocybin therapy clinical trial, in 20 sites across Europe and North America. The company received FDA Breakthrough Therapy designation for its programme of psilocybin therapy in treatment-resistant depression in 2018.
“We are delighted to be supporting COMPASS Pathways, a truly innovative mental health care company, as it progresses the clinical development of its psilocybin therapy programme. This successful fundraise is a testament to the company’s strong scientific rigour and the hard work of the COMPASS team to accelerate patient access to evidence-based innovation in mental health.”
Amber Fennell
Partner and Co-Founder of Consilium Strategic Communications
The Consilium team representing COMPASS Pathways on the financing news comprises Amber Fennell, Chris Gardner, Alix Floyd (US), David Daley, Olivia Manser, Lizzie Seeley and Maya Bennison.
To view COMPASS’s announcement please click here.
